Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Camurus and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and ...

U.S. teens are increasingly resorting to Novo Nordisk’s (NVO) popular weight loss therapy Wegovy as the country grapples with ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...